



PHARMACY EXAMINING BOARD
Contact: Dan Williams (608) 266-2112
Room 121A, 1400 East Washington Avenue, Madison, WI 53703
February 24, 2016

Notice: The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the action and deliberation of the Board.

AGENDA

11:00 A.M.

(Or immediately following the pharmacy rules committee meeting.)

OPEN SESSION – CALL TO ORDER – ROLL CALL

- A. **Adoption of Agenda (1-4)**
- B. **Approval of Minutes of January 12, 2016 (5-11)**
- C. **11:00 A.M.: Public Hearing on Clearinghouse Rule 16-017 Relating to Application and Examination (12)**
 - 1) Review and Respond to Clearinghouse Report and Public Hearing Comments
- D. **11:00 A.M.: Public Hearing on Clearinghouse Rule 16-018 Relating to Identification Card Required for Certain Controlled Substances (Act 199) (13)**
 - 1) Review and Respond to Clearinghouse Report and Public Hearing Comments
- E. **Legislation/Administrative Rule Matters – Discussion and Consideration (14)**
 - 1) Assembly Bill 841 Relating to Pilot Programs
 - 2) Update on Legislation and Pending or Possible Rulemaking Projects
- F. **Administrative Updates – Discussion and Consideration**
 - 1) Staff Updates
 - 2) Board Member – Term Expiration Date
 - a. Franklin LaDien – 7/1/2016
 - b. Terry Maves – 7/1/2018
 - c. Thaddeus Schumacher – 7/1/2019
 - d. Kristi Sullivan – 7/1/2016
 - e. Philip Trapskin – 7/1/2017
 - f. Cathy Winters – 7/1/2017
 - g. Public Member – **Vacancy**
- G. **APPEARANCE: DSPP Division of Legal Services and Compliance (DLSC) Staff - Phar 7 Pharmacist Consultation –Discussion and Consideration (15)**

- H. **APPEARANCE: DSPS Credentialing Staff - Credentialing Presentation – Discussion and Consideration (16)**
- I. **APPEARANCE: DSPS Education and Exams Staff - National Association of Boards of Pharmacy (NABP) Audit Assistance – Discussion and Consideration (17)**
- J. **Informational Items – Discussion and Consideration**
 - 1) Emergency Contraception Guide for Pharmacies **(18-22)**
 - 2) NABP Implementation of Multistate Pharmacy Jurisprudence Examination (MPJE) Program Updates **(23-24)**
 - 3) NABP Verified Pharmacy Program Update **(25-26)**
 - 4) Supplement Recall Letter **(27)**
- K. **Speaking Engagement(s), Travel, or Public Relations Request(s) – Discussion and Consideration**
 - 1) 2016 NABP Annual Meeting – May 14-17, 2016 **(28-29)**
 - 2) NABP MPJE Item-Development Workshop – March 15-16, 2016 **(30-32)**
 - 3) Report on Presentation at Concordia College of Pharmacy – February 23, 2016
- L. **Just Culture – Video Presentation (33)**
- M. **Items Received After Preparation of the Agenda**
 - 1) Introductions, Announcements and Recognition
 - 2) Election of Board Officers
 - 3) Appointment of Board Liaisons
 - 4) Administrative Updates
 - 5) Education and Examination Matters
 - 6) Credentialing Matters
 - 7) Practice Matters
 - 8) Legislation/Administrative Rule Matters
 - 9) Informational Items
 - 10) Disciplinary Matters
 - 11) Presentations of Petitions for Summary Suspension
 - 12) Petitions for Designation of Hearing Examiner
 - 13) Presentation of Proposed Stipulations, Final Decisions and Orders
 - 14) Presentation of Proposed Final Decision and Orders
 - 15) Presentation of Interim Orders
 - 16) Petitions for Re-Hearing
 - 17) Petitions for Assessments
 - 18) Petitions to Vacate Orders
 - 19) Requests for Disciplinary Proceeding Presentations
 - 20) Motions
 - 21) Petitions
 - 22) Appearances from Requests Received or Renewed
 - 23) Speaking Engagement(s), Travel, or Public Relations Request(s)
 - 24) Division of Legal Services and Compliance (DLSC) Matters
 - 25) Prescription Drug Monitoring Program Information
 - 26) Consulting with Legal Counsel

27) **Liaison Report(s)**

- a. Appointed to Controlled Substances Board per Wis. Stats. §15.405(5g): Franklin LaDien
- b. Continuing Education (CE) and Education and Examinations Liaison: Terry Maves
- c. Credentialing Liaison(s): Terry Maves, Cathy Winters
- d. Digest Liaison: Philip Trapskin
- e. DLSC Liaison: Thaddeus Schumacher, Cathy Winters
- f. Legislative Liaison: Philip Trapskin, Thaddeus Schumacher, Terry Maves
- g. Monitoring Liaison(s): Franklin LaDien, Cathy Winters
- h. PHARM Rep to State Council on Alcohol and Other Drug Abuse (SCAODA): Kristi Sullivan
- i. Pharmacy Rules Committee: Thaddeus Schumacher, Franklin LaDien, Philip Trapskin, Kristi Sullivan
- j. Professional Assistance Procedure (PAP) Liaison: Franklin LaDien
- k. Screening Panel: Cathy Winters, Kristi Sullivan, Philip Trapskin
- l. Variance Report Liaison: Philip Trapskin, Cathy Winters

N. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider closing disciplinary investigations with administrative warnings (ss. 19.85 (1)(b), and 440.205, Stats.); to consider individual histories or disciplinary data (s. 19.85 (1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

O. **Deliberation on Proposed Final Decision and Order(s) in Matter of Disciplinary Proceeding Against:**

- 1) Khushboo S. Modi, R.Ph., Respondent (DHA Case # SPS-15-0042)(DLSC Case # 14 PHM 062) **(34-42)**

P. **Deliberation on Credentialing Matters**

- 1) M.K. – Application Review (NABP License Transfer) **(43-132)**

Q. **Deliberation on Division of Legal Services and Compliance (DLSC) Matters**

- 1) **Administrative Warnings**
 - a. 15 PHM 007 (R.S.) **(133-134)**
 - b. 15 PHM 038 (B.T.P.) **(135-136)**
 - c. 15 PHM 047 (S.P.S.) **(137-138)**
- 2) **Proposed Stipulations, Final Decision and Orders**
 - a. 14 PHM 129 (A.L.H.) **(139-144)**
 - b. 15 PHM 004 (S.V.H.) **(145-150)**
 - c. 15 PHM 161 (M.L.) **(151-156)**
 - d. 15 PHM 193 (S.P.) **(157-163)**
- 3) **Case Closings**
 - a. 14 PHM 061 (I.A. and A.P.) **(164-166)**
 - b. 15 PHM 007 (Walgreens # 02927) **(167-170)**
 - c. 15 PHM 052 (W.L.) **(171-172)**
 - d. 15 PHM 123 (P.G.M.) **(173-175)**

- 4) **Monitoring Matters (176-253)**
 - a. John J. Bosnjak – Requesting Modifications **(178-204)**
 - b. Erin Orth – Requesting Full Licensure**(205-253)**

R. Deliberation of Items Received After Preparation of Agenda

- 1) Education and Examination Matters
- 2) Credentialing Matters
- 3) Disciplinary Matters
- 4) Monitoring Matters
- 5) Professional Assistance Procedure (PAP) Matters
- 6) Petitions for Summary Suspension
- 7) Petitions for Designation of Hearing Examiner
- 8) Proposed Stipulations, Final Decisions and Orders
- 9) Administrative Warnings
- 10) Review of Administrative Warnings
- 11) Proposed Final Decisions and Orders
- 12) Orders Fixing Costs/Matters Related to Costs
- 13) Case Closings
- 14) Proposed Interim Orders
- 15) Petitions for Assessments and Evaluations
- 16) Petitions to Vacate Orders
- 17) Remedial Education Cases
- 18) Motions
- 19) Petitions for Re-Hearing
- 20) Appearances from Requests Received or Renewed

S. Consult with Legal Counsel

RECONVENE INTO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

T. **Voting on Items Considered or Deliberated upon in Closed Session, if Voting is Appropriate**

U. **Board Meeting Process (Time Allocation, Agenda Items) – Discussion and Consideration**

ADJOURNMENT

The Next Scheduled Meeting is April 7, 2016.

**PHARMACY EXAMINING BOARD
MEETING MINUTES
JANUARY 12, 2016**

PRESENT: Franklin LaDien, Terry Maves, Thaddeus Schumacher, Kristi Sullivan, Philip Trapskin, Cathy Winters

STAFF: Dan Williams – Executive Director, Nilajah Hardin – Bureau Assistant, Sharon Henes – Administrative Rules Coordinator, and other Department staff

CALL TO ORDER

Thaddeus Schumacher, Chair, called the meeting to order at 11:07 a.m. A quorum of six (6) members was confirmed.

ADOPTION OF AGENDA

Amendments to the Agenda

- *Under J. 2) Proposed Stipulations, Final Decisions and Orders: Items “ a.14 PHM 056 (M.L.T.C.)” and “b.14 PHM 056 (T.J.P.)” note that the updated case advisor is now Philip Trapskin*

MOTION: Terry Maves moved, seconded by Cathy Winters, to adopt the agenda as amended. Motion carried unanimously.

APPROVAL OF MINUTES OF NOVEMBER 18, 2015

MOTION: Terry Maves moved, seconded by Cathy Winters, to approve the minutes of November 18, 2015 as published. Motion carried unanimously.

ADMINISTRATIVE UPDATES

Election of Officers

Slate of Officers

NOMINATION: Terry Maves nominated the 2015 slate of officers to continue in 2016.

Dan Williams called for nominations three (3) times.

Nomination carried by unanimous consent.

The 2015 Slate of Officers was reelected to continue in 2016.

2016 ELECTION RESULTS	
Board Chair	Thaddeus Schumacher
Vice Chair	Franklin LaDien
Secretary	Philip Trapskin

Appointment of Liaisons

2016 LIAISON APPOINTMENTS	
Continuing Education (CE) and Office of Education and Examinations Liaison	Terry Maves
Credentialing Liaison(s)	Terry Maves, Cathy Winters
Digest Liaison	Philip Trapskin
Legislative Liaison(s)	Philip Trapskin, Thaddeus Schumacher, Terry Maves
DLSC Liaison(s)	Thaddeus Schumacher, Cathy Winters
Professional Assistance Procedure (PAP) Liaison(s)	Franklin LaDien
Monitoring Liaison(s)	Franklin LaDien, Cathy Winters
Appointed to Controlled Substances Board as per Wis. Stats. §15.405(5g)	Franklin LaDien
Variance Report Liaison(s)	Philip Trapskin, Cathy Winters
PHARM Rep to SCAODA	Kristi Sullivan

2016 SCREENING PANEL APPOINTMENTS	
January - December 2016	Cathy Winters, Kristi Sullivan, Philip Trapskin

2016 COMMITTEE MEMBER APPOINTMENTS	
Pharmacy Rules Committee	Thaddeus Schumacher, Franklin LaDien, Philip Trapskin, Kristi Sullivan

MOTION: Cathy Winters moved, seconded by Kristi Sullivan, to affirm the Chair’s appointment of liaisons for 2016. Motion carried unanimously.

Delegation of Authority

Delegated Authority for Urgent Matters

MOTION: Cathy Winters moved, seconded by Kristi Sullivan, that, in order to facilitate the completion of assignments between meetings, the Board delegates its authority by order of succession to the Chair, highest ranking officer, or longest serving member of the Board, to appoint liaisons to the Department to act in urgent matters, make appointments to vacant liaison, panel and committee positions, and to act when knowledge or experience in the profession is required to carry out the duties of the Board in accordance with the law. Motion carried unanimously.

Delegated Authority for Application Denial Reviews

MOTION: Kristi Sullivan moved, seconded by Terry Maves, that the Board counsel or another department attorney is formally authorized to serve as the Board's designee for purposes of Wis. Admin Code § SPS 1.08(1). Motion carried unanimously.

Document Signature Delegation

MOTION: Cathy Winters moved, seconded by Franklin LaDien, to delegate authority to the Chair or chief presiding officer, or longest serving member of the Board, by order of succession, to sign documents on behalf of the Board. In order to carry out duties of the Board, the Chair, chief presiding officer, or longest serving member of the Board, has the ability to delegate this signature authority for purposes of facilitating the completion of assignments during or between meetings. The Chair, chief presiding officer, or longest serving member of the Board delegates the authority to Executive Director or designee to sign the name of any Board member on documents as necessary and appropriate. Motion carried unanimously.

Credentialing Authority Delegations

MOTION: Terry Maves moved, seconded by Kristi Sullivan, to delegate authority to the Credentialing Liaisons to address all issues related to credentialing matters. Motion carried unanimously.

MOTION: Cathy Winters moved, seconded by Kristi Sullivan, to delegate credentialing authority to DSPS for those submitted applications that meet the criteria of Rule and Statute and thereby would not need further Board or Board liaison review. Motion carried unanimously.

Monitoring Delegation

MOTION: Terry Maves moved, seconded by Kristi Sullivan, to adopt the 'Roles and Authorities Delegated to the Monitoring Liaison and Department Monitor; document as presented. Motion carried unanimously.

Education Delegations

MOTION: Kristi Sullivan moved, seconded by Franklin LaDien, to delegate authority to the Continuing Education (CE) and Office of Education and Examination Liaison(s) to address all issues related to CE, education and examinations. Motion carried unanimously.

Variance Report Delegation

MOTION: Terry Maves moved, seconded by Cathy Winters, to delegate authority to the Variance Report Liaison(s) to address all issues related to variance report matters. Motion carried unanimously.

Rules Committee

MOTION: Kristi Sullivan moved, seconded by Cathy Winters, to grant the Rules Committee the ability to address all rule making language. Motion carried unanimously.

CLOSED SESSION

MOTION: Franklin LaDien moved, seconded by Philip Trapskin, to convene to closed session to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider closing disciplinary investigations with administrative warnings (ss. 19.85 (1)(b), and 440.205, Stats.); to consider individual histories or disciplinary data (s. 19.85 (1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.). Thaddeus Schumacher, Chair, read the language of the motion. The vote of each member was ascertained by voice vote. Roll Call Vote: Franklin LaDien –yes; Terry Maves-yes; Thaddeus Schumacher-yes; Kristi Sullivan- yes; Philip Trapskin-yes; Cathy Winters-yes. Motion carried unanimously.

The Board convened into Closed Session at 12:47 p.m.

RECONVENE TO OPEN SESSION

MOTION: Franklin LaDien moved, seconded by Terry Maves, to reconvene into open session. Motion carried unanimously.

The Board reconvened into Open Session at 2:41 p.m.

VOTING ON ITEMS CONSIDERED OR DELIBERATED ON IN CLOSED SESSION

MOTION: Kristi Sullivan moved, seconded by Terry Maves, to affirm all motions made in closed session. Motion carried unanimously.

DIVISION OF LEGAL SERVICES AND COMPLIANCE (DLSC) MATTERS

Administrative Warning(s)

15 PHM 007 – R.S.

MOTION: Philip Trapskin moved, seconded by Kristi Sullivan, to table the Administrative Warning in the matter of 15 PHM 007 (R.S.). Motion carried. Abstained: Franklin LaDien

Proposed Stipulation(s), Final Decision(s) and Order(s)

14 PHM 055 – D.A.O

MOTION: Philip Trapskin moved, seconded by Cathy Winters, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against David A. Obermeyer, R.Ph., DLSC case number 14 PHM 055. Motion carried. Recused: Franklin LaDien

(Franklin LaDien recused himself and left the room for deliberation, and voting in the matter concerning David A. Obermeyer, R.Ph., DLSC case number 14 PHM 055.)

14 PHM 056 – M.L.T.C.

MOTION: Cathy Winters moved, seconded by Philip Trapskin, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against Morton, LTC., DLSC case number 14 PHM 056. Motion carried. Recused: Terry Maves

(Terry Maves recused himself and left the room for deliberation, and voting in the matter concerning Morton, LTC., DLSC case number 14 PHM 056.)

14 PHM 056 – T.J.P.

MOTION: Cathy Winters moved, seconded by Philip Trapskin, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against Timothy J. Price, R.Ph., DLSC case number 14 PHM 056. Motion carried. Recused: Terry Maves

(Terry Maves recused himself and left the room for deliberation, and voting in the matter concerning Timothy J. Price, R.Ph., DLSC case number 14 PHM 056.)

14 PHM 078 – S.H.

MOTION: Philip Trapskin moved, seconded by Kristi Sullivan, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against Stephen Herbst, R.Ph., DLSC case number 14 PHM 078. Motion carried. Recused: Thaddeus Schumacher

(Thaddeus Schumacher recused himself and left the room for deliberation, and voting in the matter concerning Stephen Herbst, R.Ph., DLSC case number 14 PHM 078.)

14 PHM 109 – M.P.P.

MOTION: Terry Maves moved, seconded by Kristi Sullivan, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against Medical Park Pharmacy, DLSC case number 14 PHM 109. Motion carried unanimously.

14 PHM 144 – T.C.W.

MOTION: Philip Trapskin moved, seconded by Cathy Winters, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against Thomas C. Wilke, R.Ph., DLSC case number 14 PHM 144. Motion carried. Abstained: Terry Maves

15 PHM 170 – D.L.

MOTION: Philip Trapskin moved, seconded by Terry Maves, to adopt the Findings of Fact, Conclusions of Law and Order in the matter of disciplinary proceedings against Downing Labs, LLC., R.Ph., DLSC case number 15 PHM 170. Motion carried unanimously.

Case Closings

MOTION: Cathy Winters moved, seconded by Franklin LaDien, to close the DLSC cases for the reasons outlined below:

1. 14 PHM 145 (A.I.S.) - Prosecutorial Discretion (P2)
 2. 15 PHM 108 (H.P.) - Prosecutorial Discretion (P2)
 3. 15 PHM 108 (T.H.E.) - Prosecutorial Discretion (P2)
 4. 15 PHM 109 (P.D.W.) - Prosecutorial Discretion (P2)
 5. 15 PHM 109 (T.M.S.) - Prosecutorial Discretion (P2)
 6. 15 PHM 110 (A.K.S.) - Prosecutorial Discretion (P2)
 7. 15 PHM 110 (M.P.I.) - Prosecutorial Discretion (P2)
 8. 15 PHM 111 (B.E.N.) - Prosecutorial Discretion (P2)
 9. 15 PHM 111 (R.C.P.I.) - Prosecutorial Discretion (P2)
 10. 15 PHM 112 (N.L.S.) - Prosecutorial Discretion (P2)
 11. 15 PHM 112 (S.P.) - Prosecutorial Discretion (P2)
 12. 15 PHM 158 (L.S.C.P.) - Prosecutorial Discretion (P2)
 13. 15 PHM 159 (P.L.) - Prosecutorial Discretion (P2)
 14. 15 PHM 164 (M.C.P.) - Prosecutorial Discretion (P2)
 15. 15 PHM 165 (W.H.P.) - Prosecutorial Discretion (P2)
 16. 15 PHM 171 (T.P.) - Prosecutorial Discretion (P2)
 17. 15 PHM 174 (D.M.P.) – No Violation
 18. 15 PHM 177 (M.P.) - Prosecutorial Discretion (P2)
 19. 15 PHM 179 (T.P.) - Prosecutorial Discretion (P2)
 20. 15 PHM 190 (A.C.P.) - Prosecutorial Discretion (P2)
 21. 15 PHM 194 (O.R.) - Prosecutorial Discretion (P2)
 22. 15 PHM 196 (I.A.) - Prosecutorial Discretion (P2)
- Motion carried unanimously.

12 PHM 035

MOTION: Philip Trapskin moved, seconded by Franklin LaDien, to close DLSC case number 12 PHM 035, against M.S, for Prosecutorial Discretion (P7). Motion carried unanimously.

14 PHM 078

MOTION: Philip Trapskin moved, seconded by Kristi Sullivan, to close DLSC case number 14 PHM 078, against M.P, for Prosecutorial Discretion (P2). Motion carried. Recused: Thaddeus Schumacher

(Thaddeus Schumacher recused himself and left the room for deliberation, and voting in the matter concerning M.P., DLSC case number 14 PHM 078.)

14 PHM 078

MOTION: Philip Trapskin moved, seconded by Kristi Sullivan, to close DLSC case number 14 PHM 078, against P.V., for Prosecutorial Discretion (P2). Motion carried. Recused: Thaddeus Schumacher

(Thaddeus Schumacher recused himself and left the room for deliberation, and voting in the matter concerning P.V, DLSC case number 14 PHM 078.)

15 PHM 007

MOTION: Philip Trapskin moved, seconded by Terry Maves, to table DLSC case number 15 PHM 007, against Walgreens #02927. Motion carried. Abstained: Franklin LaDien

Monitoring

Jay Bubrick, R. Ph. – Request to Surrender License

MOTION: Philip Trapskin moved, seconded by Cathy Winters, to grant the request of Jay Bubrick, R.Ph. for the surrender of his Pharmacist License. Motion carried unanimously.

ORDER(S) FIXING COSTS

Marvin Moore, R.Ph., Respondent (ORDER00004402)(DHA Case # SPS-15-0026)(DLSC Case # 12 PHM 035)

MOTION: Philip Trapskin moved, seconded by Kristi Sullivan, to adopt the Order Fixing Costs in the matter of disciplinary proceedings against Marvin Moore, R.Ph., Respondent (ORDER00004402)(DHA Case # SPS-15-0026)(DLSC Case # 12 PHM 035). Motion carried unanimously.

ADJOURNMENT

MOTION: Franklin LaDien moved, seconded by Terry Maves, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 2:58 p.m.

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Sharon Henes Administrative Rules Coordinator		2) Date When Request Submitted: 15 February 2016 Items will be considered late if submitted after 12:00 p.m. on the deadline date: ▪ 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 24 February 2016	5) Attachments: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Public Hearing on Clearinghouse Rule 16-017 relating to application and examination Review and respond to Clearinghouse Report and Public Hearing comments	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? <input type="checkbox"/> Yes (Fill out Board Appearance Request) <input type="checkbox"/> No	9) Name of Case Advisor(s), if required:	
10) Describe the issue and action that should be addressed: Hold Public Hearing at 11:00 a.m. Discuss any public hearing comments. Review, discuss and respond to any Clearinghouse comments.			
11) Authorization			
<i>Sharon Henes</i>		<i>15 February 2016</i>	
Signature of person making this request		Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda) Date			
Directions for including supporting documents: 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, Provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Sharon Henes Administrative Rules Coordinator		2) Date When Request Submitted: 15 February 2016 Items will be considered late if submitted after 12:00 p.m. on the deadline date: ▪ 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 24 February 2016	5) Attachments: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Public Hearing on Clearinghouse Rule 16-018 relating to identification card required for certain controlled substances (Act 199) Review and respond to Clearinghouse Report and Public Hearing comments	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? <input type="checkbox"/> Yes (Fill out Board Appearance Request) <input type="checkbox"/> No	9) Name of Case Advisor(s), if required:	
10) Describe the issue and action that should be addressed: Hold Public Hearing at 11:00 a.m. Discuss any public hearing comments. Review, discuss and respond to any Clearinghouse comments.			
11) Authorization <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center; width: 45%;"> <p style="font-size: 1.2em; font-family: cursive;"><i>Sharon Henes</i></p> <hr/> <p>Signature of person making this request</p> </div> <div style="text-align: center; width: 45%;"> <p style="font-size: 1.2em; font-family: cursive;"><i>15 February 2016</i></p> <hr/> <p>Date</p> </div> </div> <hr/> <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center; width: 45%;"> <p>Supervisor (if required)</p> <hr/> </div> <div style="text-align: center; width: 45%;"> <p>Date</p> <hr/> </div> </div> <hr/> <div style="display: flex; justify-content: space-between; align-items: center;"> <div style="text-align: center; width: 45%;"> <p>Executive Director signature (indicates approval to add post agenda deadline item to agenda)</p> <hr/> </div> <div style="text-align: center; width: 45%;"> <p>Date</p> <hr/> </div> </div>			
Directions for including supporting documents: 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, Provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Sharon Henes Administrative Rules Coordinator		2) Date When Request Submitted: 15 February 2016 Items will be considered late if submitted after 12:00 p.m. on the deadline date: ▪ 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Pharmacy Examining Board			
4) Meeting Date: 24 February 2016	5) Attachments: <input type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Legislation and Rule Matters – Discussion and Consideration 1. AB 841 Relating to pilot programs 2. Update on Legislation and Pending and Possible Rulemaking Projects	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? <input type="checkbox"/> Yes (Fill out Board Appearance Request) <input type="checkbox"/> No	9) Name of Case Advisor(s), if required:	
10) Describe the issue and action that should be addressed:			
11) Authorization			
<i>Sharon Henes</i>		<i>15 February 2016</i>	
Signature of person making this request		Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda)		Date	
Directions for including supporting documents: 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, Provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Dan Williams		2) Date When Request Submitted: Items will be considered late if submitted after 4:30 p.m. and less than: <ul style="list-style-type: none"> ▪ 10 work days before the meeting for Medical Board ▪ 14 work days before the meeting for all others 	
3) Name of Board, Committee, Council, Sections: Wisconsin Pharmacy Examining Board			
4) Meeting Date: Feb. 24, 2016	5) Attachments: <input type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? PHAR 7 Pharmacist consultation – Discussion and Consideration	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? If yes, who is appearing? <input type="checkbox"/> Yes by <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required: N/A	
10) Describe the issue and action that should be addressed: The Department’s Division of Legal Services and Compliance (DLSC) will make an appearance before the Board to discuss Pharmacist consultation.			

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Philip Trapskin		2) Date When Request Submitted: Items will be considered late if submitted after 4:30 p.m. and less than: <ul style="list-style-type: none"> ▪ 10 work days before the meeting for Medical Board ▪ 14 work days before the meeting for all others 	
3) Name of Board, Committee, Council, Sections: Wisconsin Pharmacy Examining Board			
4) Meeting Date: Feb. 24, 2016	5) Attachments: <input type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? DSPS credentialing presentation – Discussion and Consideration	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? If yes, who is appearing? <input type="checkbox"/> Yes by <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required: N/A	
10) Describe the issue and action that should be addressed: <p style="color: blue;">Agenda time for a presentation by the appropriate person or persons within DSPS to provide the Board an overview of the processes for new license applications, for renewals (including the timing and messaging on the postcards), process for pharmacists that do not renew on time.</p>			

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Philip Trapskin		2) Date When Request Submitted: Items will be considered late if submitted after 4:30 p.m. and less than: <ul style="list-style-type: none"> ▪ 10 work days before the meeting for Medical Board ▪ 14 work days before the meeting for all others 	
3) Name of Board, Committee, Council, Sections: Wisconsin Pharmacy Examining Board			
4) Meeting Date: Feb. 24, 2016	5) Attachments: <input type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? NABP audit assistance – Discussion and Consideration	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? If yes, who is appearing? <input type="checkbox"/> Yes by <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required: N/A	
10) Describe the issue and action that should be addressed: <p style="margin-left: 40px;">I think the Board would appreciate some investigation with NABP about what is possible as it relates to states auditing the CPE Monitor for compliance with CE requirements (e.g. 30 hours over each renewal period). I think Rocky was interested in using the NABP tool to do the auditing and changing our rules to require all CE be documented in this tool to count towards the biannual requirement. Philip</p>			

From: Jamie Bass [mailto:jamie@americansocietyforec.org]
Sent: Wednesday, February 10, 2016 2:33 PM
To: Williams, Dan - DSPS; DSPS
Cc: Kelly C. Cleland; Rachel Suppe; Rafie, Sally
Subject: Request for Board Dissemination of Information Regarding Emergency Contraception for Public Health Benefit

Dear Colleague,

I'm writing on behalf of the American Society for Emergency Contraception, where an important part of our mission is expanding access to and education about emergency contraception (EC), as well as assessing the state of access to the medication in pharmacies. In our most recent study ([Inching Towards Progress: ASEC's 2015 Pharmacy Access Study](#)) we found that, despite the fact that levonorgestrel EC pills (such as Plan B One-Step) are FDA-approved for OTC sale without age or point-of-sale restrictions, many stores don't stock it on the shelf, and others continue to enforce out-of-date age restrictions.

We are working hard to help share information with pharmacists around the country about the regulations around EC, so that customers don't face barriers to accessing this very time-sensitive medication. We developed an EC guide for pharmacies in partnership with the American College of Clinical Pharmacy Women's Health Practice & Research Network and the Reproductive Health Technologies Project ([Emergency Contraception: A Guide for Pharmacies and Retailers](#)) and are distributing it to individual pharmacies and Boards of Pharmacy around the country. We would greatly appreciate if your Board could disseminate this information in your state. We know that pharmacists and Boards of Pharmacy are committed to high-quality care, and imagine that the disappointing state of access to emergency contraception in pharmacies is due to an information gap, rather than efforts to obstruct access. We would welcome the opportunity to share more information with you and colleagues in your state and can be available as clinical experts to answer any questions from the Board or to do an educational presentation.

Thank you for your attention and we hope to hear from you.

All the best,

Jamie Bass

Jamie Bass, MPH
American Society for Emergency Contraception
jamie@americansocietyforec.org | **skype: jamie.bass81** | www.americansocietyforec.org

February 10, 2016

To: State Boards of Pharmacy
Pharmacy Professional Associations
Pharmacy Corporations

Re: Emergency Contraception Guide for Pharmacies

As advocates for direct pharmacy access and over-the-counter access to emergency contraception (EC), the undersigned organizations encourage state boards of pharmacy, professional pharmacy associations, and pharmacy corporations to facilitate access by disseminating resources to pharmacists, pharmacy staff, and the public. States with pharmacist EC protocols in place have an additional opportunity to ensure timely access to this medication.

In the past several years, there have been numerous new EC products and changes in regulations, such as restricting access based on age or checking identification. As a result, pharmacists and pharmacy staff are often unable to keep up with the latest products and changes. This has led to misinformation to the public and refusals to sell over-the-counter EC products, most commonly related to presumed age or gender restrictions.

Some key findings from recent studies of pharmacy access to EC:

- EC is available in 80% of pharmacies [Wilkinson et al. 2012; Samson et al. 2013; Rafie et al. 2013].
- Pharmacy staff members regularly give misinformation about age restrictions for EC: in one study, staff gave incorrect information to 43% of consumers and 39% physicians who called asking about EC [Wilkinson et al. 2012]. Callers are often put on hold or passed between multiple pharmacy staff members to get answers to their questions about EC [Wilkinson et al. 2012; Nelson et al. 2009].
- Young men are denied EC at pharmacies that require the presence of a female or her identification card [Bell et al. 2015; Wilkinson et al. 2014].

To address the knowledge and awareness deficits among pharmacists, pharmacy staff, and consumers alike, we encourage boards of pharmacy, professional pharmacy associations, and pharmacy corporations to make accurate information available to public consumers, as well as their licensees, members, and employees. Suggested resources include a pharmacy guide to the various EC products, EC locator tools, and patient education materials and websites.

A concise and comprehensive guide on EC product availability and access has been developed to serve as an easy reference to stay current on access issues and available products. This guide is intended for use as a reference for pharmacists, as well as pharmacy or store management and staff.

The guide is updated as needed and can be found on the American Society for Emergency Contraception (ASEC) website:

http://americansocietyforec.org/uploads/3/2/7/0/3270267/pharmacy_ec_access_overview.pdf.

The guide is also available in Spanish:

http://americansocietyforec.org/uploads/3/2/7/0/3270267/pharmacy_ec_access_overview_spanish.pdf

as well as in a version that does not mention any specific product brands or prices:

http://americansocietyforec.org/uploads/3/4/5/6/34568220/pharmacy_board_ec_guide_2016.pdf.

This guide was developed by ASEC in collaboration with the American College of Clinical Pharmacy Women's Health Practice and Research Network and the Reproductive Health Technologies Project. Organizations are welcome to adapt this guide to meet their needs.

Pharmacies are encouraged to stock EC products and make them available on the over-the-counter shelves as well, in order to minimize barriers to access. Pharmacists can help provide evidence-based counseling on medications, in addition to referrals for more effective methods of contraception and sexually transmitted infection screening/treatment. Please refer to specific state laws regarding refusals for personal objections.

Sincerely,



Kelly Cleland, MPA MPH
Executive Director
American Society for Emergency Contraception



Jessica Arons
President & CEO
Reproductive Health Technologies Project



Brooke Griffin, PharmD, BCACP
Chair
American College of Clinical Pharmacy Women's Health Practice & Research Network

EMERGENCY CONTRACEPTION: A GUIDE FOR PHARMACIES AND RETAILERS (JUNE 2015)

What is emergency contraception (also known as “the morning-after pill”)?

- Emergency contraception (EC) prevents pregnancy; EC will not disrupt an existing pregnancy.
- EC pills that contain the progestin hormone, levonorgestrel (LNG), are sold under several names. Most levonorgestrel EC products are available over-the-counter (OTC) without age restrictions. (See reverse side for specific medication details.)
- EC pills that contain ulipristal acetate are available and are prescription only.
- All EC works best when taken as soon as possible after unprotected sex but may be effective up to 5 days after.
- EC is safe for women of all ages to use.

What are the restrictions for purchasing EC over-the-counter? Do customers need to show ID?

- For the one-pill LNG EC products containing one 1.5 mg levonorgestrel pill (brand and generics), there are NO age or point-of-sale restrictions. Previously, OTC purchases were subject to age restrictions, but these have been removed by the U.S. Food and Drug Administration (FDA) and most brands have updated their labels to reflect the new regulations.
 - Any woman or man of any age can purchase these EC products without needing to show ID.
 - There is no limit on the number of packages that a person can purchase.
 - Although some of the generic one-pill product labels state that the product is intended for women aged 17 and older, this is not a restriction on sale (no ID required); it is guidance for the consumer only.
- For the two-pill LNG EC products containing two 0.75 mg levonorgestrel pills, there are still age restrictions and these must be kept behind the pharmacy counter. A pharmacy staff member must check ID to ensure the person purchasing the product is age 17 or older, but a pharmacist consultation is not required.

Can men purchase LNG EC?

- Yes, men can purchase over-the-counter LNG EC. There are no sex/gender restrictions on the sale of any over-the-counter products. However, prescriptions for EC can only be issued to the patient who will be taking it.

Where can EC be found within pharmacies and stores?

- Pharmacies and retailers can sell one-pill LNG EC products directly from store shelves as long as the products have updated OTC packaging.
 - Most retailers stock it in the family planning aisle so it can be found easily.
 - There is no need for these EC products to be kept behind the pharmacy counter.
- Two-pill LNG EC products must still be stocked behind the pharmacy counter. The customer can purchase the product without a prescription if they are at least 17 years old. Patients aged 16 or younger will need a prescription. Some states may have protocols that allow the pharmacist to provide a prescription directly to patients.
 - You may consider removing these products from your stock unless they are cheaper than the one-pill products. The one-pill product is easier for patients to take and there's no chance of not taking the second pill at the right time.
- Ulipristal acetate is available by prescription only so it must be kept behind the pharmacy counter. Some states may have protocols that allow the pharmacist to provide a prescription directly to patients.

Why is it important to stock one-pill LNG EC on the shelf?

- EC is a woman's last chance to prevent an unintended pregnancy after birth control failure, sexual assault, or unprotected sex.
- EC works best when it's taken as soon as possible. Convenient and timely access is critically important.
- Keeping EC behind the counter is an unnecessary and harmful barrier; FDA has approved these EC products to be sold on store shelves without any restrictions.
- Customers may feel embarrassed about purchasing EC; placing it directly on the shelf without locked security boxes protects people's privacy and confidentiality.
- Pharmacies and stores have an important role to play in helping women prevent unintended pregnancy by maintaining a stock of easily accessible EC on the shelf at all times.

What can I do if my store doesn't stock one-pill LNG EC on the shelf?

- If you are the person who makes stocking decisions, you can make space for EC in the family planning aisle.
- If your store doesn't sell EC on the shelf, it may be because the regulations around EC have changed frequently in the past few years, and it can be confusing. Share these guidelines with your management and encourage them to stock EC on the shelf.
- If you cannot fulfill a customer's request for EC, please refer them to Not-2-Late's EC locator: www.not-2-late.com.

FDA-APPROVED EMERGENCY CONTRACEPTIVE PILLS AS OF JUNE 2015

Under current regulations, the medications listed below should be made available in the following ways:

MEDICATION	INFORMATION
<p>Brand and Generic <u>One-Pill</u> Levonorgestrel EC Products</p>	<ul style="list-style-type: none"> • May be stocked on OTC shelves in stores. • Label may indicate that the product is intended for use by women ages 17 and older, but ID check is <u>not</u> required. • Take as soon as possible; may be effective up to 5 days after unprotected sex. • 1 tablet (1.5 mg levonorgestrel)
<p>Generic <u>Two-Pill</u> Levonorgestrel EC Product</p>	<ul style="list-style-type: none"> • Must be stocked behind the pharmacy counter. • Prescription required for those 16 years and younger. Available for purchase over-the-counter for those 17 and older. • Only EC product that is currently "dual labeled" for prescription and OTC usage. • Take both pills together as soon as possible; may be effective up to 5 days after unprotected sex. • 2 tablets (each 0.75 mg levonorgestrel)
<p>Ulipristal acetate</p>	<ul style="list-style-type: none"> • Must be stocked in the pharmacy as a prescription-only drug. • Available for purchase by prescription at the pharmacy. • Only EC product labeled for prescription use only. • Take as soon as possible; effective up to 5 days after unprotected sex. • 1 tablet (30 mg ulipristal acetate)

If you have questions or want to share comments about how EC is sold at your store, contact us:
asec@americansocietyforec.org.

Learn more about EC at www.not-2-late.com and www.rhtp.org.



nabp

National Association of Boards of Pharmacy

1600 Feehanville Drive • Mount Prospect, IL 60056-6014

Tel: 847/391-4406 • Fax: 847/391-4502

Web Site: www.nabp.net

TO: EXECUTIVE OFFICERS – STATE BOARDS OF PHARMACY
FROM: Carmen A. Catizone, Executive Director/Secretary
DATE: January 7, 2015
RE: Implementation of MPJE Program Updates

The National Association of Boards of Pharmacy[®] (NABP[®]) would like to notify the boards of pharmacy regarding the implementation of the updates to the Multistate Pharmacy Jurisprudence Examination[®] (MPJE[®]). Beginning April 15, 2016, the MPJE will be assembled under the new competency statements, and the number of examination items, the maximum time allowed for the examination, and the registration fee will increase. The timeline for implementing these changes is outlined below along with details on how the information will be communicated to candidates taking the MPJE in 2016.

Registration Deadlines

Registration for the current MPJE will remain open through April 3, 2016. Candidates must complete their registration with NABP for the current MPJE by April 3, 2016. These candidates must obtain eligibility from the board, receive an authorization to test (ATT), schedule with Pearson VUE, and sit for the exam on or before April 10, 2016.

If a candidate registers for the MPJE by April 3, but does not take the exam on or before April 10, 2016, their registration will be canceled and their fee of \$210 will be refunded. The candidate will then need to register for the updated exam on or after April 12, 2016. The board will need to grant eligibility to test for candidates completing a new registration. Candidates who schedule resits but do not take the exam by April 10, 2016, will receive a refund of the \$90 resit fee, and they must then register for the updated MPJE and pay the \$250 registration fee. No refunds will be issued for change of jurisdiction.

EXECUTIVE OFFICERS – STATE BOARDS OF PHARMACY

January 7, 2016

Page 2

New Graduates

Candidates who will not meet graduation requirements in time to complete the registration, eligibility, and scheduling steps outlined above are advised by NABP to wait to register until registration opens for the updated MPJE.

Registration for the updated MPJE opens April 12, 2016. The fee will be \$250. The updated MPJE will be administered beginning April 15, 2016. The number of examination items will increase from 90 (75 scored and 15 pre-test) to 120 (100 scored and 20 pre-test) and the maximum testing time will increase from two hours to two and a half hours.

A new passing standard for the MPJE will be implemented on April 15, 2016; however, the scaled score required to pass will remain at 75. It is typical to see variations in the pass rates after a new standard is in place.

Detailed information on the above changes is included in the 2016 *NAPLEX/MPJE Candidate Registration Bulletin* which will be available tomorrow on the NABP website.

Communication to Candidates

In addition to the information provided in the *Bulletin*, candidates will be informed of the upcoming MPJE changes through additional communications. Messaging in the online registration system now informs students about the upcoming changes and registration deadlines for the current MPJE. The messaging directs them to the *Bulletin* for details.

This week, deans of schools and colleges of pharmacy will be sent via email a PDF flyer that they may distribute and post to alert students of the upcoming MPJE changes. Deans will be encouraged to tell students graduating after April 3, 2016, to wait to register for the updated MPJE.

In addition, beginning in January, candidates who have open MPJE registrations will be notified of the deadlines via email. Prior to refunds being issued to candidates not completing the exam by April 10, a reminder message regarding the refund process and the need to grant eligibility for new MPJE registrations will be sent to the boards.

Additional details about the changes to the MPJE were included in the memo sent October 8, 2015, and will also be included in the February 2016 *NABP Newsletter*.

If there are any questions regarding the MPJE updates or the implementation process, please contact Maria Incrocci, competency assessment senior manager, at mincrocci@nabp.net or 847/391-4406.

cc: NABP Executive Committee



National Association of Boards of Pharmacy

1600 Feehanville Drive • Mount Prospect, IL 60056-6014

Tel: 847/391-4406 • Fax: 847/391-4502

Web Site: www.nabp.net

nabp

TO: EXECUTIVE OFFICERS – STATE BOARDS OF PHARMACY
FROM: Carmen A. Catizone, Executive Director/Secretary
DATE: January 14, 2016
RE: Verified Pharmacy Program Update

To date, more than 345 pharmacies have applied to the Verified Pharmacy Program[®] (VPP[™]) and currently or soon will have verified data available in NABP e-Profile Connect. Of these pharmacies, nearly 30 have reapplied for a more current inspection after having been inspected previously through VPP. As a result of these applications, critical data including but not limited to inspection reports, license verifications, disciplinary actions, and pharmacy demographics is available through NABP e-Profile Connect.

As mentioned in previous communications, VPP was built to serve as a comprehensive information sharing network for the member boards of pharmacy with the ultimate goal of supporting the states' robust inspection programs by facilitating the communication of inspection data between the boards and only conducting inspections when there is a need to supplement the capacity of a state's existing inspection program. To ensure that the lines of communication remain open, the National Association of Boards of Pharmacy[®] (NABP[®]) continues to send VPP-related notifications to designated individuals at the state boards of pharmacy.

VPP Notifications and Alerts

Notifications are sent via email to the board of pharmacy contact(s) as designated by the executive officer. This information includes items such as:

- Notification emails to the resident board of upcoming VPP inspections in their state.
- Notification emails alerting of the availability of a new VPP inspection bundle (inspection report, license verification, and disciplinary actions) for a pharmacy seeking licensure, currently licensed, or previously licensed in the state. **This email contains brief information on whether the facility is compounding, the inspection date, and the specific areas where any noncompliance may have been recorded. The full report and profile information is accessible in NABP e-Profile Connect.**
- Weekly email containing a list of the available VPP inspection reports in NABP e-Profile Connect.
- Occasional VPP updates.

Alerts of new documentation in the system are available directly through NABP e-Profile Connect and are visible in the Alerts Tab once an individual logs in to the VPP responsibility. These include, but are not limited to, newly uploaded:

- VPP applications
- VPP Inspection reports*
- State Inspection Reports
- Pharmacy Responses
- Other miscellaneous notifications and correspondence from the pharmacy or other entities such as recalls, closures, pharmacist-in-charge changes, etc

***Once a VPP pharmacy is inspected, an inspection report is compiled and bundled as a PDF with additional documentation including supplemental inspection documents (if applicable), a licensure verification summary, and board order documents (if applicable). This PDF is then uploaded to the pharmacy's e-Profile in NABP e-Profile Connect for the states to view to when making any determinations relating to licensure. Those states where the applicant holds licensure, as well as those where the facility is seeking licensure, will be able to view an alert of the new documentation in their Alerts Tab.**

Designated Contacts and Access to VPP Through NABP e-Profile Connect

In most cases, the designated contact to receive the email notifications is the executive officer of the board of pharmacy unless he or she has designated another individual to receive the communications. Likewise, all executive officers should have direct access to the VPP responsibility within NABP e-Profile Connect where the full data and inspection reports are housed.

Note: Though multiple individuals may have access to the VPP responsibility in NABP e-Profile Connect, email notifications are sent manually and are only sent to the executive officer or his or her designee.

The executive officer has the authority to designate other board of pharmacy staff to have direct access to VPP for the purpose of performing inspection services for the board. He or she may designate an individual by sending an email to Lawana Lyons, licensure programs senior manager, at llyons@nabp.net with the individual's name, position with the board, and email address. Likewise, if a staff member leaves the board of pharmacy, we request that the board please inform NABP so that he or she may be removed from the access list.

If you have any questions regarding the VPP process and notifications, or you need to make any updates to your designated VPP contacts, please contact VPP staff at vpp@nabp.net, or you may contact Lisa Huxhold directly at 847-391-4469 or lhuxhold@nabp.net.

Thank you.

cc: NABP Executive Committee

February 10, 2016

Not for Public Disclosure

To Whom This May Concern:

I am writing to inform you of a recent voluntary recall conducted at our facility at Hartley Medical Pharmacy Inc. in Long Beach, CA. The notification of this recall consisted of the Pharmacist-in-Charge telephonically contacting the affected clients and informing them verbally. We are well into the process of recovering all recalled preparations from our clients and can confirm that **no patients** received any medication involved in this recall. We have begun an investigation to assess the root cause of this event.

On Thursday, February 4, 2016, we initiated a recall regarding sterile products that were compounded on February 3, 2016, within a single, specific LAFW. The recall event was triggered due to a pharmacy technician's noticing a less than normal sound output coming from the particular LAFW and presenting the noise issue to a pharmacist at approximately 11:00 am on February 4. The technician expressed a suspicion that the day before, the LAFW had exhibited a similar noise level. After some discussion, the switch for the LAFW motor was pressed. At this moment, the staff noticed an increase in the sound level from this specific LAFW. The staff then assumed that the LAFW had not been running properly.

Based on this assumption, all preparations compounded on February 4, 2016, in this particular LAFW were destroyed. Preparations which were compounded in this LAFW on February 3, 2016, and then shipped to clients were then determined to become the subject to this recall.

The quality of these preparations could not be determined to be within the standards of our policies and procedures which is why we are issuing a voluntary recall of these affected products. This does not mean that the preparations are **non-sterile** or pose a **life-threatening health issue**. All of our sterile compounding occurs in an ISO Class 6 clean room with proper sterilization technique applied during compounding. Our procedures require daily microbial monitoring of each staff member and of all critical surfaces. This routine monitoring of the LAFW and the technician resulted in negative microbial presence.

We wish to be completely transparent; and we will continue to update you on this matter until it is completely resolved. The quality of our products and the safety of our patients is our primary concern. If you have any additional clarifications or questions, please contact William A. Stuart, RPh, at 562-595-7548 or at wstuart@hartleymedical.com

Respectfully yours,

William A. Stuart, RPh
Pharmacist in Charge
President
Hartley Medical Center Pharmacy, Inc.

Confidential

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Dan Williams		2) Date When Request Submitted: Items will be considered late if submitted after 4:30 p.m. and less than: <ul style="list-style-type: none"> ▪ 10 work days before the meeting for Medical Board ▪ 14 work days before the meeting for all others 	
3) Name of Board, Committee, Council, Sections: Wisconsin Pharmacy Examining Board			
4) Meeting Date: Feb. 24, 2016	5) Attachments: <input type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? 2016 NABP annual meeting May 14-17, 2016 – Discussion and Consideration	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both		8) Is an appearance before the Board being scheduled? If yes, who is appearing? <input type="checkbox"/> Yes by <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required: N/A
10) Describe the issue and action that should be addressed: The Board will need to delegate a member to attend on their behalf for the NABP annual meeting in San Diego, CA, May 14-17, 2016.			



**NATIONAL ASSOCIATION
BOARDS OF PHARMACY
FOUNDATION**

TO: EXECUTIVE OFFICERS – ACTIVE MEMBER STATE BOARDS OF PHARMACY

FROM: Carmen A. Catizone, Executive Director/Secretary

DATE: January 8, 2016

RE: Annual Meeting Travel Grant Program for NABP's 112th Annual Meeting, May 14-17, 2016, San Diego, CA

The National Association of Boards of Pharmacy Foundation (NABP Foundation) is pleased to continue the Annual Meeting Travel Grant Program for NABP members needing financial assistance to attend NABP Annual Meetings. NABP feels that it is essential for boards of pharmacy to participate in Annual Meetings because during this time NABP's member boards of pharmacy will vote upon Association resolutions, select Executive Committee officers and members, and present and discuss information on current issues facing pharmacy regulators.

For the past 112 years, the mission of NABP has been to aid and support pharmacy regulators in creating standards that protect the public health. NABP realizes that budget constraints can prevent state boards of pharmacy from sending representatives to meetings, so the Annual Meeting Travel Grant Program will reimburse the board's designee **up to \$1,500** in travel fees to defray expenses such as airfare, hotel rooms, meals, taxis, parking, and tips. Grant monies do not include Annual Meeting registration fees. Monies are limited and grants are available on a first-come, first-served basis. Please note that the NABP Annual Meeting Travel Grant reimbursement policy requires individuals to pay for all airfare, meals, hotel accommodations, and other meeting costs up front, and submit an expense report and original receipts to NABP after the Annual Meeting in order to receive reimbursement.

One individual per active member board of pharmacy is eligible to receive the grant. **Though the individual awarded the travel grant need not be the board of pharmacy's voting delegate, his or her board of pharmacy must have a voting delegate in attendance at the Annual Meeting to vote during all applicable business sessions in order to receive reimbursement.**

The chief administrative officer of the board must complete the attached application form to apply for the travel grant, or to request the grant be awarded to a current board member from his or her state. NABP must receive all applications before the 112th Annual Meeting, May 14-17, 2016, San Diego, CA. NABP will inform applicants whether or not they have qualified for a grant, and at that time provide them with more detailed instructions on procedures for reimbursement.

For more information, please contact Lisa Braddy, at 847/391-4400, ext 4462. We request that you complete the attached document, and return via e-mail to exec-office@nabp.net prior to the Annual Meeting.

Attachment: Annual Meeting Travel Grant Application



National Association of Boards of Pharmacy

1600 Feehanville Drive • Mount Prospect, IL 60056-6014
Tel: 847/391-4406 • Fax: 847/391-4502
Web Site: www.nabp.net

nabp

TO: EXECUTIVE OFFICERS – MPJE PARTICIPATING STATES, MPJE Item Writers, and MPJE Review Committee

FROM: Maria Incrocci, Competency Assessment Senior Manager

DATE: January 7, 2016

RE: MPJE Item-Development Workshop – March 15-16, 2016

The National Association of Boards of Pharmacy® (NABP®) will host the Multistate Pharmacy Jurisprudence Examination® (MPJE®) Item Development Workshop on March 15-16, 2016, at NABP Headquarters in Mount Prospect, IL. The two-day meeting will begin with an overview of the MPJE program, followed by an instructional session on item development led by NABP staff. Members from the MPJE Review Committee will be in attendance to assist attendees and to facilitate the meeting. The item development process is a collaborative effort and NABP encourages all MPJE participating states to attend this important workshop.

The tentative meeting schedule is as follows (all times are CST).

Tuesday, March 15: 8:30 AM to 5 PM (Group dinner to follow)

Wednesday, March 16: 8:30 AM to 3:00 PM

NABP will reimburse approved expenses (travel, food, and lodging) for two participants from each state to attend the workshop. However, NABP may need to limit the attendance to one participant from each state in the event of space limitations. If your state board is unable to send a representative, the assignment will need to be completed remotely. Full details including content areas to be targeted and logistics will be provided at a later date to the designated item writer(s).

Please provide contact information on the response form for the individual(s) assigned to attend the workshop or for those individuals who will complete the state assignment remotely. The NABP Meeting Services department will forward travel and hotel information approximately six weeks prior to the meeting once NABP has secured the name(s) of the attendee(s).

NABP has recently developed a single database for all volunteer item writers. We will be including MPJE board-appointed writers in this database for more efficient communications. We request that all MPJE item writers complete this very brief questionnaire on FormSite so we have a complete record of

all MPJE item writers. To access the questionnaire, please visit
<http://fs23.formsite.com/NationalAssociationofBoardsofPharmacy/form4/index.html>.

If you have any questions or comments please contact me at mincrocci@nabp.net or 847/391-4426; or contact Anne Woolridge, competency assessment coordinator at awoolridge@nabp.net or 847/391-4534.

2016 MPJE Item Development

Please indicate your state’s commitment to the 2016 Multistate Pharmacy Jurisprudence Examination® (MPJE®) item development assignment by indicating either attendance at the workshop taking place March 15-16, 2016, **or** remote participation. This form is in a fillable format. It requires Adobe Reader 6.0 or higher. Open the file, add the information, and click “yes” to save the changes. Please email this form to Anne Woolridge at awoolridge@nabp.net or fax it to 847/391-4503 no later than **Friday, February 12, 2016.**

State Board: _____

____ Attending the MPJE workshop at National Association of Boards of Pharmacy® Headquarters.

____ NOT attending; will complete the assignment remotely.

MPJE Item Writer Contact Information

Please provide the contact information for the individuals who will attend the MPJE Workshop **or** will be completing the writing assignment remotely.

Item Writer: _____

Phone: _____

Email: _____

Item Writer: _____

Phone: _____

Email: _____

Item Writer: _____

Phone: _____

Email: _____

**State of Wisconsin
Department of Safety & Professional Services**

AGENDA REQUEST FORM

1) Name and Title of Person Submitting the Request: Philip Trapskin		2) Date When Request Submitted: Items will be considered late if submitted after 4:30 p.m. and less than: <ul style="list-style-type: none"> ▪ 10 work days before the meeting for Medical Board ▪ 14 work days before the meeting for all others 	
3) Name of Board, Committee, Council, Sections: Wisconsin Pharmacy Examining Board			
4) Meeting Date: Feb. 24, 2016	5) Attachments: <input type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Just Culture – Discussion and Consideration	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session <input type="checkbox"/> Both	8) Is an appearance before the Board being scheduled? If yes, who is appearing? <input type="checkbox"/> Yes by <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if required: N/A	
10) Describe the issue and action that should be addressed: <p style="text-align: center;">I would like to request agenda time to discuss “Just Culture” perhaps even watch this short video https://www.justculture.org/david-marx-introduces-just-culture/</p>			